Karyon Ltd’s operations focus on the discovery, IP protection and early development of carrier peptides that target specific tissues. The targeting peptides are identified from ex vivo patient tumour tissue and further synthetically modified at Karyon Ltd. Linking a diagnostic marker or therapeutic regimen to the targeting peptide enriches compound concentration in the target organ.
| Karyon targeting unit | Target indications |
| Karyon TCTP Tumour cell targeting peptides |
Sarcoma, melanoma, kaposi’s sarcoma |
| Karyon AETP Activated endothelium targeting peptides |
Conditions of angiogenic origin |
| Karyon Thx-1 Non small cell lung cancer targeting peptide |
Non small cell lung cancer |
| Karyon LMC Lung metastases |
Colon cancer lung metastases |
| Karyon OrCa Oral cancer targeting peptides |
Lingual and gingival cancer forms |
| Karyon LyMe Lymph sentinel node metastases |
Head and neck lymph sentinel node metastases |
Karyon Ltd’s scientists are pleased to assist your company’s diagnostic or therapeutic compound find its tumour target.